ERBB2 and breast carcinoma: In order to limit cardiac damages, newer protocols recommend 1 year of trastuzumab therapy in patients with HER2-positive breast cancer ≥1.0 cm in size; even after 1 year, treatment still is interrupted due to cardiotoxicity in 13.6% of patients (31).